• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form DEFA14A filed by Kodiak Sciences Inc

    4/23/24 4:23:56 PM ET
    $KOD
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Get the next $KOD alert in real time by email
    DEFA14A 1 d899653ddefa14a.htm DEFA14A DEFA14A

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

    SCHEDULE 14A

    PROXY STATEMENT PURSUANT TO SECTION 14(a) OF THE

    SECURITIES EXCHANGE ACT OF 1934

    (Amendment No.  )

    Filed by the Registrant ☒   Filed by a Party other than the Registrant ☐

    Check the appropriate box:

     

    ☐

     

      

    Preliminary Proxy Statement

     

    ☐

     

      

    Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2))

     

    ☐

     

      

    Definitive Proxy Statement

     

    ☒

     

      

    Definitive Additional Materials

     

    ☐    Soliciting Material Pursuant to §240.14a-12

    KODIAK SCIENCES INC.

     

    (Name of Registrant as Specified In Its Charter)

     

     

    (Name of Person(s) Filing Proxy Statement, if other than the Registrant)

    Payment of Filing Fee (Check all boxes that apply):

     

    ☒

     

      

    No fee required

     

    ☐

     

      

    Fee paid previously with preliminary materials

     

    ☐

     

      

    Fee computed on table in exhibit required by Item 25(b) per Exchange Act Rules 14a-6(i)(1) and 0-11

     

     

     

     


    LOGO

    Kodiak P.O. BOX 8016, CARY, NC 27512-9903 Your vote matters! Kodiak Sciences Inc. 2024 Annual Meeting of Stockholders Tuesday, June 4, 2024 9:00 AM, Pacific Time Annual Meeting to be held live via the Internet - please visit www.proxydocs.com/KOD for more details. You must register to attend the meeting online and/or participate or vote at the meeting at www.proxydocs.com/KOD For a convenient way to view proxy materials, VOTE, and obtain instructions to attend the meeting and vote at the meeting, go to www.proxydocs.com/KOD To vote your proxy while visiting this site, you will need the 12 digit control number in the box below. This communication presents only an overview of the more complete proxy materials that are available to you on the Internet. This is not a ballot. You cannot use this notice to vote your shares. We encourage you to access and review all of the important information contained in the proxy materials before voting. Under United States Securities and Exchange Commission rules, proxy materials do not have to be delivered in paper. Proxy materials can be distributed by making them available on the Internet. If you want to receive a paper or e-mail copy of the proxy material, which include the Notice and Proxy Statement and Annual Report, you must request one. You will not otherwise receive a paper or e-mail copy. There is no charge to you for requesting a copy. In order to receive a paper package in time for this year’s meeting, you must make this request on or before May 24, 2024. SEE REVERSE FOR FULL AGENDA Scan QR for digital voting Important Notice Regarding the Availability of Proxy Materials for the Stockholders Meeting to be Held on June 4, 2024 For Stockholders of record as of April 5, 2024 To order paper materials, use one of the following methods. Internet: www.investorelections.com/KOD Call: Toll-Free 1-866-648-8133 E-mail: [email protected] * If requesting material by e-mail, please send a blank e-mail with the 12 digit control number (located below) in the subject line. No other requests, instructions OR other inquiries should be included with your e-mail requesting material. Go Green! To receive documents via e-mail, simply go to: www.proxydocs.com/KOD Your control number Have the 12 digit control number located in the box above available when you access the website and follow the instructions. Copyright © 2024 BetaNXT, Inc. or its affiliates. All Rights Reserved


    LOGO

    Kodiak Kodiak Sciences Inc. 2024 Annual Meeting of Stockholders THE BOARD OF DIRECTORS RECOMMENDS A VOTE: FOR ON PROPOSALS 1, 2 AND 3 PROPOSAL 1. Elect two Class lll directors nominated by our board and named in this proxy statement. 1.01 Felix J. Baker, Ph.D. 1.02 Victor Perlroth, M.D. 2. Approve, on an advisory basis, the compensation of Kodiak’s named executive officers, as disclosed in the proxy statement. 3. Ratify the appointment of PricewaterhouseCoopers LLP as our independent registered public accounting firm for the year ending December 31, 2024. NOTE: In their discretion, the proxies are authorized to vote upon such other business as may properly come before the meeting or any adjournments or postponents thereof.

    Get the next $KOD alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $KOD

    DatePrice TargetRatingAnalyst
    11/11/2025$24.00Neutral → Buy
    H.C. Wainwright
    10/24/2025$24.00Neutral → Overweight
    Analyst
    9/25/2025$17.00Underweight → Equal Weight
    Barclays
    9/22/2025$15.00Buy
    Jefferies
    8/14/2025$15.00Underweight → Neutral
    Analyst
    12/9/2024$20.00Hold → Buy
    Jefferies
    9/5/2024$3.00Neutral
    H.C. Wainwright
    12/11/2023$2.00Sell
    Goldman
    More analyst ratings

    $KOD
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Baker Bros. Advisors Lp bought $60,000,008 worth of shares (2,608,696 units at $23.00) (SEC Form 4)

    4 - Kodiak Sciences Inc. (0001468748) (Issuer)

    12/19/25 4:06:09 PM ET
    $KOD
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form 4 filed by Officer Borgeson John A.

    4 - Kodiak Sciences Inc. (0001468748) (Issuer)

    7/8/25 4:33:23 PM ET
    $KOD
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form 4 filed by Chairman and CEO Perlroth Victor

    4 - Kodiak Sciences Inc. (0001468748) (Issuer)

    7/8/25 4:30:46 PM ET
    $KOD
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $KOD
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Baker Bros. Advisors Lp bought $60,000,008 worth of shares (2,608,696 units at $23.00) (SEC Form 4)

    4 - Kodiak Sciences Inc. (0001468748) (Issuer)

    12/19/25 4:06:09 PM ET
    $KOD
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $KOD
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Kodiak Sciences upgraded by H.C. Wainwright with a new price target

    H.C. Wainwright upgraded Kodiak Sciences from Neutral to Buy and set a new price target of $24.00

    11/11/25 8:00:12 AM ET
    $KOD
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Kodiak Sciences upgraded by Analyst with a new price target

    Analyst upgraded Kodiak Sciences from Neutral to Overweight and set a new price target of $24.00

    10/24/25 8:56:02 AM ET
    $KOD
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Kodiak Sciences upgraded by Barclays with a new price target

    Barclays upgraded Kodiak Sciences from Underweight to Equal Weight and set a new price target of $17.00

    9/25/25 8:23:23 AM ET
    $KOD
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $KOD
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Final APEX Phase 1b Clinical Results for Kodiak's KSI-101 in Macular Edema Secondary to Inflammation to be Presented at Angiogenesis 2026

    PALO ALTO, Calif., Feb. 4, 2026 /PRNewswire/ -- Kodiak Sciences Inc. (NASDAQ:KOD), a precommercial retina focused biotechnology company committed to researching, developing and commercializing transformative therapeutics, announced today participation at the virtual Angiogenesis (Angiogenesis, Exudation, and Degeneration) annual meeting on February 7, 2026. Dr. Sumit Sharma, retina and uveitis specialist at the Cole Eye Institute, will present first-time end-of-study clinical results, including Week 24 data, from the Phase 1b APEX study in patients with macular edema secondary to inflammation (MESI). Presentation title: Bispecific Trap-antibody Inhibiting Interleukin-6 and Vascular Endothel

    2/4/26 7:00:00 AM ET
    $KOD
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Kodiak Sciences to Present at 44th Annual J.P. Morgan Healthcare Conference

    PALO ALTO, Calif., Jan. 7, 2026 /PRNewswire/ -- Kodiak Sciences Inc. (NASDAQ:KOD), a precommercial retina focused biotechnology company committed to researching, developing and commercializing transformative therapeutics, announced today that senior management will present at the 44th Annual J.P. Morgan Healthcare Conference in San Francisco, CA on Monday, January 12, 2026, at 1:30 p.m. Pacific Time. A live webcast of the presentation will be available on the "Events and Presentations" section of Kodiak's website at http://ir.kodiak.com/ and will remain available for replay for a limited time following the event. About Kodiak Sciences Inc. Kodiak Sciences (NASDAQ:KOD) is a precommercial ret

    1/7/26 8:19:00 PM ET
    $KOD
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Kodiak Sciences Announces Closing of $184 Million Public Offering of Common Stock including Full Exercise of Underwriters' Option to Purchase Additional Shares

    PALO ALTO, Calif., Dec. 18, 2025 /PRNewswire/ -- Kodiak Sciences Inc. (NASDAQ:KOD), a precommercial retina focused biotechnology company committed to researching, developing and commercializing transformative therapeutics, today announced the closing of its previously announced underwritten public offering of 8,000,000 shares of its common stock, which includes 1,043,478 shares sold pursuant to the underwriters' exercise in full of their option to purchase additional shares, at a price to the public of $23.00 per share. The gross proceeds to Kodiak Sciences from the offering were approximately $184 million, before deducting the underwriting discounts and commissions and estimated offering ex

    12/18/25 8:26:00 PM ET
    $KOD
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $KOD
    SEC Filings

    View All

    Amendment: SEC Form SCHEDULE 13D/A filed by Kodiak Sciences Inc

    SCHEDULE 13D/A - Kodiak Sciences Inc. (0001468748) (Subject)

    12/19/25 4:22:14 PM ET
    $KOD
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form 8-K filed by Kodiak Sciences Inc

    8-K - Kodiak Sciences Inc. (0001468748) (Filer)

    12/18/25 4:25:35 PM ET
    $KOD
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form 424B5 filed by Kodiak Sciences Inc

    424B5 - Kodiak Sciences Inc. (0001468748) (Filer)

    12/17/25 5:27:33 PM ET
    $KOD
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $KOD
    Leadership Updates

    Live Leadership Updates

    View All

    Kodiak Sciences to Host Investor R&D Day on September 23, 2024 in New York City

    PALO ALTO, Calif., Sept. 17, 2024 /PRNewswire/ -- Kodiak Sciences Inc. (NASDAQ:KOD), a biopharmaceutical company committed to researching, developing and commercializing transformative therapeutics to treat a broad spectrum of retinal diseases, announced today that it will host an Investor R&D Day with financial analysts and institutional investors on Monday, September 23, 2024, in New York City from 10:30 am ET to 12:30 pm ET. The event will feature presentations and roundtable discussions on Kodiak's science of durability, science of the enhanced formulation, timeline and other updates for the Company's active clinical pipeline, and the Company's expanding Antibody Biopolymer Conjugate Dr

    9/17/24 4:05:00 PM ET
    $KOD
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Pipeline Therapeutics Appoints Julie Iwashita as Vice President of Clinical Operations

    SAN DIEGO--(BUSINESS WIRE)--Pipeline Therapeutics, a biopharmaceutical company focused on the development and commercialization of first-in-class small molecules for neuroregeneration, today announced the appointment of Julie Iwashita as the company’s Vice President of Clinical Operations. Ms. Iwashita brings more than 30 years of experience guiding global neurology and other clinical development programs through the U.S. Food and Drug Administration (FDA) and other global health authorities. “I am delighted to welcome Julie to Pipeline Therapeutics to spearhead our clinical development efforts,” said Carmine Stengone, President & CEO of Pipeline Therapeutics. “Julie’s extensive

    12/3/20 11:00:00 AM ET
    $KOD
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $KOD
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G/A filed by Kodiak Sciences Inc (Amendment)

    SC 13G/A - Kodiak Sciences Inc. (0001468748) (Subject)

    2/14/24 4:23:00 PM ET
    $KOD
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form SC 13G/A filed by Kodiak Sciences Inc (Amendment)

    SC 13G/A - Kodiak Sciences Inc. (0001468748) (Subject)

    1/26/24 11:49:38 AM ET
    $KOD
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form SC 13G/A filed by Kodiak Sciences Inc (Amendment)

    SC 13G/A - Kodiak Sciences Inc. (0001468748) (Subject)

    2/14/23 4:19:55 PM ET
    $KOD
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $KOD
    Financials

    Live finance-specific insights

    View All

    Kodiak Sciences to Report Fourth Quarter and Full-Year 2023 Financial Results and Host Business Updates Webcast on March 28, 2024

    PALO ALTO, Calif., March 26, 2024 /PRNewswire/ -- Kodiak Sciences Inc. (NASDAQ:KOD), a biopharmaceutical company committed to researching, developing and commercializing transformative therapeutics to treat high prevalence retinal diseases, announced today that it will report fourth quarter and full-year 2023 financial results on Thursday, March 28, 2024. Management will host a conference call and live webcast to discuss recent business highlights and provide a corporate update at 4:30 p.m. Eastern Time on March 28, 2024. To access the webcast, please register at https://edge.media-server.com/mmc/p/q4jdxku4/. A live audio webcast of the event will be available on the "Events and Presentatio

    3/26/24 6:15:00 AM ET
    $KOD
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Kodiak Sciences Announces Top-Line Results from its initial Phase 2b/3 Study of KSI-301 in Patients with Neovascular (Wet) Age-Related Macular Degeneration

    PALO ALTO, Calif., Feb. 23, 2022 /PRNewswire/ -- Kodiak Sciences Inc. (NASDAQ:KOD) today announced top-line results from its randomized, double-masked, active comparator-controlled Phase 2b/3 clinical trial evaluating the efficacy, durability and safety of KSI-301, a novel antibody biopolymer conjugate, in treatment-naïve subjects with neovascular (wet) age-related macular degeneration. The trial randomized 559 participants, approximately 80% of whom were enrolled in the United States. The study had two treatment arms: KSI-301 5mg on a flexible long-interval regimen and aflibercept 2mg on a fixed short-interval regimen. In the study, three monthly loading doses were administered to all subje

    2/23/22 6:00:00 AM ET
    $KOD
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care